Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.61 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | CCR3 | P51677 | 3/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594577 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A3SLC6A4OPRK1HRH1 | |
| SCHEMBL3594573 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A3SLC6A4OPRK1HRH1 | |
| Hydrochloric Acid SCHEMBL3605902 | 0.99 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4OPRK1HRH1 | |
| Hydrochloric Acid SCHEMBL3605898 | 0.99 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4OPRK1HRH1 | |
| Hydrochloric Acid SCHEMBL4232921 | 0.99 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4OPRK1HRH1 | |
| SCHEMBL1028365 | 0.86 | SLC6A2 (0.68) | SLC6A2SLC6A3SLC6A4OPRK1KCNH2 | |
| SCHEMBL1028366 | 0.86 | SLC6A2 (0.68) | SLC6A2SLC6A3SLC6A4OPRK1KCNH2 | |
| SCHEMBL1177552 | 0.85 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4OPRK1KCNH2 | |
| SCHEMBL1177550 | 0.85 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4OPRK1KCNH2 | |
| SCHEMBL1177828 | 0.82 | SLC6A2 (0.64) | SLC6A2SLC6A3OPRK1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | SLC6A2 1701/4885SLC6A3 839/4885SLC6A4 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.